United Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- United Therapeutics
- Registration Number
- NCT01884038
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Starzl Transplantation Institute, Pittsburgh, Pennsylvania, United States
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
- Conditions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 98
- Registration Number
- NCT01799473
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸The Regents of the University of California, La Jolla, California, United States
🇺🇸Southern California Permanente, Pasadena, California, United States
Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT01795950
- Locations
- 🇦🇺
The Prince Charles Hospital, Brisbane, Queensland, Australia
🇦🇺The Alfred Hospital, Melbourne, Australia
Three Times Daily Dosing of UT-15C
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT01746485
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT01592045
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Remodulin® to Oral Treprostinil Transition
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT01588405
- Locations
- 🇺🇸
Arizona Pulmonary Specialists, Phoenix, Arizona, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 690
- Registration Number
- NCT01560624
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States
🇨🇳The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 471
- Registration Number
- NCT01560637
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Indiana University Hospital, Carmel, Indiana, United States
🇺🇸Asheville Cardiology Associates, Asheville, North Carolina, United States
Inhaled Treprostinil for PAH: Open-label Extension
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- United Therapeutics
- Registration Number
- NCT01557660
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
- Conditions
- Interventions
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- United Therapeutics
- Registration Number
- NCT01557647